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Aging is a natural phenomenon which is
peculiar to all living organisms. However,
it is believed by some scientists that senes-
cence could be postponed or prevented by
certain approaches. Some dietary ingredi-
ents and supplements have been suggested
to have anti-aging and life-extending
effects. Natural and synthetic dietary sup-
plements including anti-oxidants, vita-
mins, and hormones are among the most
popular products on the market, even
without solid scientific evidence support-
ing their efficacy (Olshansky et al., 2002).
Recently, a number of synthetic drugs
used for various therapeutic applications
have also been assumed to have anti-aging
potential (Kapoor et al., 2009). In most
cases, however, the high expectations for
these drugs were not fulfilled. The effects
of several substances, e.g., anti-oxidants,
have been supported by data obtained in
animal models, but when carefully con-
trolled human trials have been conducted,
questions about the efficacy and safety of
these substances have emerged (Jerome-
Morais et al., 2011). Excessive intake of
anti-oxidants, vitamins, or hormones is
known to destroy delicate control mech-
anisms of homeostatic balance, and it is
not yet clear under which conditions, if
any, they may have a long-term benefi-
cial impact on life expectancy in humans
(Cochemé and Murphy, 2010). Given this
situation, it is necessary to increase the
choice of chemical compounds which have
the potential to positively affect longevity.
In this Opinion, we present arguments
that the development of specific drugs
which target epigenetic pathways could be
a highly promising anti-aging strategy.
Epigenetic factors including DNA
methylation, histone modifications,
and alteration in microRNA expres-
sion play key roles in controlling
changes in gene expression and genomic
instability throughout the human lifespan.
Epigenetic modifications are finely bal-
anced and highly reversible in normal
tissues. However, they may be imbal-
anced and heritable in tumor and other
abnormal cells. Epigenetic dysregulation
has a causal effect on age-associated dis-
orders including cancer, atherosclerosis,
type 2 diabetes, neurodegenerative and
psychiatric diseases, and the decline in
immune response (Berdasco and Esteller,
2012). There is increasing evidence to
indicate that epigenetic mechanisms are
intimately involved in synaptic plasticity
and are essential for learning and memory.
Dysfunction of epigenetic gene expression
in the brain may be involved in neu-
rodegenerative and psychiatric diseases
(Sananbenesi and Fischer, 2009; Berdasco
and Esteller, 2012).
Therefore, there is nothing surprising
in the fact that, at present, great expec-
tations in the treatment of diseases are
associated with the use of so-called “epi-
genetic drugs” that can modulate the
activity of enzymes capable of causing epi-
genetic changes. In this context, members
of the superfamily of histone deacety-
lases (HDACs) comprising HDAC 1–11
and sirtuins (SIRT) 1–7 are currently the
focus of significant interest (de Oliveira
et al., 2012). The potential reversibility
of epigenetic aberrations has made them
attractive targets for therapeutic interven-
tion. Several drugs which target the epige-
netic machinery, such as HDAC modula-
tors, mainly inhibitors, have recently been
used in human clinical trials, and some
have been recommended for the treatment
of age-associated diseases (Gryder et al.,
2012; Price et al., 2012; Sato, 2012).
Above all, HDAC inhibitors are con-
sidered promising anti-cancer therapeu-
tics (Karagiannis and Maulik, 2012).
Recently, HDAC inhibitors have shown
anti-tumor activity against certain hema-
tological malignancies; their therapeu-
tic potential in solid tumors remains
more uncertain (Gryder et al., 2012).
Vorinostat and romidepsin have recently
been approved for the treatment of
relapsed or refractory T-cell lymphoma in
the USA and Japan (Price et al., 2012; Sato,
2012). Numerous studies have identified
HDAC inhibitors as candidate drugs for
the treatment of neurodegenerative disor-
ders. These agents can ameliorate deficits
in synaptic plasticity, cognition, and stress-
related behaviors in a wide range of neu-
rologic and psychiatric disorders including
Huntington’s disease, Parkinson’s disease,
Alzheimer disease, anxiety and mood dis-
orders, Rubinstein–Taybi syndrome, and
Rett syndrome (Abel and Zukin, 2008;
Xu et al., 2011). HDAC inhibitors are
also a new class of immunomodula-
tory and anti-inflammatory therapeutics
(Akimova et al., 2012; Cantley et al., 2012;
Licciardi and Karagiannis, 2012). Recent
data identified an essential role for HDAC
inhibitors in regulation of the expression
of innate immune genes and host defenses
against microbial pathogens (Roger et al.,
2011). The anti-cancer effects of HDAC
inhibitors may also be linked to long-
term stimulation of the immune response
(Leggatt and Gabrielli, 2012).
In recent years, high hopes have been
placed on the therapeutic potential of
modulators of NAD-dependent class III
histone deacetylases (sirtuins). Sirtuins
are becoming increasingly recognized as
attractive novel therapeutic targets for
metabolic, cardiovascular and neurode-
generative diseases, and cancer (Huber and
Superti-Furga, 2011; Carafa et al., 2012).
Both activation and inhibition of sirtu-
ins may be useful for preventing and
treating age-related diseases, depending on
the pathological condition, and the target
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tissue (Mahajan et al., 2011). A number
of sirtuin inhibitors demonstrated anti-
proliferative effects in cell assays as well
as in mouse tumor models, thus suggest-
ing a possible role in cancer therapy. The
selective inhibitor of SIRT2, AGK-2, has
been reported to have protective effects
against Parkinson’s disease, and resveratrol
and other sirtuin activators can be use-
ful in the treatment of Alzheimer’s disease
(Mai, 2010).
HDACs are global transcriptional reg-
ulators; they affect gene expression by
deacetylation of not only histones but also
non-histone proteins, including transcrip-
tion factors, and are involved in the regu-
lation of signal transduction, cell cycle and
cell growth, DNA damage response, apop-
tosis, and differentiation. Sirtuins have
been implicated in determining the bal-
ance between apoptosis, cell survival, and
cell proliferation, and are also involved in
the regulation of metabolism and stress,
two key factors that affect the process
of aging (Satoh et al., 2011). The ther-
apeutic effects of HDAC inhibitors are
based on their ability to affect the tran-
scription of various genes; in particular,
anti-tumor effects can be attributed to
the transcriptional reactivation of silent
tumor suppressor genes and the tran-
scriptional repression of proto-oncogenes
(Boumber and Issa, 2011). Overall, as a
major mechanism of transcriptional reg-
ulation, protein acetylation is a key con-
troller of many physiological processes
essential for themaintenance of homeosta-
sis and a healthy lifespan. Consequently, it
is believed that the development of spe-
cific drugs which target HDAC activity
could be a highly promising anti-aging
strategy.
Indeed, the efficiency of promising
anti-aging dietary compounds, such
as resveratrol and curcumin, can by
explained, at least partly, by their ability
to modulate gene expression via interac-
tion with HDACs. For example, resveratrol
has been shown to inhibit HDAC activity
in a concentration-dependent manner
(Dayangaç-Erden et al., 2009). Albeit
the action of resveratrol is complex, the
resveratrol-induced SIRT1 activation is
believed to be the main reason for its anti-
aging effect (Price et al., 2012). Some of
the biological activities of curcumin, such
as its anti-oxidative, anti-inflammatory,
anti-cancer, chemopreventive, and anti-
neurodegenerative effects, may be due to
its capability to modulate gene expres-
sion through its interaction with HDACs,
histone acetyltransferases, DNA methyl-
transferases, and microRNAs (Reuter
et al., 2011). For example, in the study
by Lee et al. (2011) curcumin-induced
apoptosis and cell cycle arrest at the
G2/M phase in medulloblastoma cells
were accompanied by reduced HDAC4
expression.
Among the chemicals affecting HDAC
activity, HDAC inhibitors are obvious can-
didates for the role of anti-aging agents.
Indeed, a decrease in HDAC activity would
lead to increased transcription of many
genes. With age, the transcription profiles
of different genes change in different ways.
However, for the majority of genes, pri-
marily metabolic and biosynthetic genes,
a decline in transcription is observed in
old age (Lee et al., 1999; Seroude et al.,
2002). There is hope thatHDAC inhibition
will promote temporal homeostasis and
delay aging due to preservation of the level
of transcription, which is characteristic of
the young, in aging organisms. In addi-
tion, HDAC inhibition may result in up-
regulation of inflammatory response and
stress response genes—changes that are
usually associated with increased longevity
(Vermeulen and Loeschcke, 2007; Kourtis
and Tavernarakis, 2011).
It still remains an enigma how fine-
tuning of the expression of different genes
necessary for normal functioning of an
organism could be provided in this case.
An imbalance in HDAC activity, simi-
lar to an imbalance in the supply of
anti-oxidants, vitamins, or hormones, can
destroy delicate control mechanisms pro-
viding homeostasis. However, it is worth
mentioning that epigenetic regulation of
gene transcription is a highly coordi-
nated process mediated by central regu-
latory mechanisms, which can take over
functions necessary for a proper orches-
tration of epigenetic interventions. It
makes epigenetics an attractive candidate
molecular mechanism suited for the con-
trol of highly integrated biological pro-
cess such as aging (Vaiserman, 2011).
Alternatively, one can expect that stage-,
tissue-, and HDAC-specific inhibitors will
be developed. A similar approach is now
being implemented with respect to protein
kinase inhibitors, aimed at treating var-
ious diseases, especially cancer (Lamba
and Ghosh, 2012). Certainly, use of epige-
netic drugs can havemultiple and complex
effects on different systems and tissues. For
example, one side effect of modulation of
epigenetic processes aimed at human life
extension could be reduced reproductive
activity. However, the reproductive capa-
bilities of modern people can in fact be
realized only very partially due to social
(but not biological!) reasons. Therefore,
such price for long life span does not seem
too high.
Notwithstanding all doubts, in recent
years, experimental research has emerged
on the life-extending potential of syn-
thetic HDAC inhibitors. A substantial
increase in both mean and maximum
survival by up to 30–50% without diminu-
tion of locomotor activity, resistance to
stress, or reproductive ability was observed
by feeding Drosophila melanogaster the
HDAC inhibitor, PBA (4-phenylbutyrate),
throughout adulthood (Kang et al., 2002).
Flies fed PBA showed a global increase
in histone acetylation accompanied by
a dramatically altered pattern of gene
expression of numerous genes, includ-
ing genes putatively involved in enhancing
longevity: superoxide dismutase, elonga-
tion factor 1, glutathione S-transferase,
cytochrome P450, and three chaper-
ones. All these genes were induced by
PBA. Tao et al. (2004) found that the
HDAC inhibitor, trichostatin A (TSA),
significantly extended the lifespan of
flies. Furthermore, TSA promoted hsp22
gene transcription. In another study con-
ducted by Zhao et al. (2005), the HDAC
inhibitors, TSA, and sodium butyrate,
were also shown to significantly extend
the lifespan and promote hsp22 and hsp70
expression in Drosophila. In our recent
study, flies fed sodium butyrate at concen-
trations of 10 and 20mmol/l throughout
both pre-adult and adult stages demon-
strated significant increases in mean
lifespan in both males and females com-
pared with controls; moreover, treatment
with 20 and 40mmol/l sodium butyrate
during the adult stage only resulted in
a statistically significant increase in male
(but not female) lifespan (Vaiserman et al.,
2012). The exact molecular mechanisms
of these positive effects remain to be elu-
cidated. In particular, it would be good
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to know whether anti-aging effects of
epigenetic drugs inmodel animals have the
same molecular basis as their therapeutic
effects in humans.
In conclusion, understanding the
molecular mechanisms underlying the
protective role of HDAC inhibitors and
other modulators of epigenetic processes
could bring us closer to the development
of novel drug targets for age-associated
chronic diseases. In our opinion, this
approach may also provide a new way
for the development of efficient anti-aging
treatments.
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